Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy

Sponsor
Central South University (Other)
Overall Status
Unknown status
CT.gov ID
NCT01761149
Collaborator
(none)
60
1
2

Study Details

Study Description

Brief Summary

Extensive clinical studies have shown that intraoperative infusion high dose of remifentanil (0.2ug/kg/min) induced postoperative hyperalgesia. Recent experimental study however suggests that higher dose of remifentanil may attenuate postoperative hyperalgesia. Thus, the present study is designed as a "proof of principle" study and hypothesizes that higher dose of remifentanil may reduce postoperative pain in patients.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Remifentanil, an ultra-short acting opioid, is widely used in the patients undergoing surgery. However, extensive studies report that remifentanil,administered at 0.2ug/kg/min or 0.4ug/kg/min intraoperatively, can result in postoperative hyperalgesia and increase the consumption of analgesics when compared with low dose (0.05ug/kg/min). However, a recent experimental study shows that large dose of remifentanil can inhibit pain hypersensitivity through erasing the spinal sensitization of pain. The present study thus hypothesizes that higher dose of remifentanil (1.2ug/kg/min) may attenuate postoperative pain. The present study will compare the effect of two different dose of remifentanil (0.2ug/kg/min and 1.2ug/kg/min) on postoperative pain. Patients undergoing thyroidectomy will be recruited, and mechanical threshold will be measured in the remote region of surgical site preoperatively. The patients will be randomly divided by two groups, 0.2ug/kg/min (group I) and 1.2ug/kg/min (group II). After operation, mechanical threshold and visual analogue scale (VAS) will be measured as the indicators of postoperative pain. The consumption of morphine will also be compared between these two doses of remifentanil.

The present study may find optimized dose of opioid usage in the patients undergoing surgery to relieve the postoperative pain.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial
Study Start Date :
Dec 1, 2012
Anticipated Primary Completion Date :
Mar 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Remifentanil (Low dose)

remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;

Drug: Remifentanil
The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)

Experimental: Remifentanil (High dose)

The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.

Drug: Remifentanil
The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)

Outcome Measures

Primary Outcome Measures

  1. Changes of sensory threshold from baseline to postoperative 24hours [24 hour]

    Quantitative sensory threshold in the remote uninjured site (here, the inner forearm) is commonly used to examine the occurrence of postoperative hyperalgesia. The present study will examine the mechanical threshold in two different doses of remifentanil to determine whether high dose of remifentanil induces hyperalgesia

Secondary Outcome Measures

  1. visual analogue score (VAS) [24 hours]

    VAS is widely used to assess postoperative pain. It will be divided as 10 points. Zero refers to no pain and ten refers to extremely pain. Based on this way, we can know the difference of postoperative pain in these two different groups.

Other Outcome Measures

  1. consumption of morphine postoperatively [24 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ASA Grade I or II

  • Age 18-60 years old

  • BMI<35,

Exclusion Criteria:
  • do not consent,

  • Chronic pain,

  • used pain killer,

  • undergoing operation previously

  • diabetes or the other diseases affecting the sensory.

  • difficult intubation;

  • unexpected surgical complication such as bleeding;

  • psychiatric disorders;

  • drug or alchohol abuse

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Anesthesiology, The Second Xiangya Hospital Changsha Hunan China 410011

Sponsors and Collaborators

  • Central South University

Investigators

  • Principal Investigator: Ru-Ping Dai, MD, Central South University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ru-Ping Dai, Associate Professor, MD, PhD, Central South University
ClinicalTrials.gov Identifier:
NCT01761149
Other Study ID Numbers:
  • XYEYYCT2013001
First Posted:
Jan 4, 2013
Last Update Posted:
Jan 4, 2013
Last Verified:
Jan 1, 2013
Keywords provided by Ru-Ping Dai, Associate Professor, MD, PhD, Central South University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 4, 2013